Clinical factors of the risk of hyperplastic endometry processes on tamoxifen therapy with breast cancer: Retrospective population study
- Authors: Golubenko E.O.1, Savelyeva M.I.2, Poddubnaya I.V.1, Korennaya V.V.1
-
Affiliations:
- Russian Medical Academy of Continuous Professional Education
- Yaroslavl State Medical University
- Issue: Vol 25, No 1 (2023)
- Pages: 63-67
- Section: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/132795
- DOI: https://doi.org/10.26442/18151434.2023.1.202117
- ID: 132795
Cite item
Full Text
Abstract
Background. One of the main stages of the treatment of breast cancer (BC) is endocrine therapy with tamoxifen or aromatase inhibitors. Five years of adjuvant tamoxifen therapy reduces the risk of disease recurrence by 39%. Tamoxifen was approved by the U.S. Food and Drug Administration in 1977 as a treatment for ER-positive BC. However, sometime after the start of tamoxifen's wide use, reports have been published on its long-term adverse effects. Most common were hot flashes, gynecological symptoms (vaginal dryness, vaginal discharge), depression, forgetfulness, sleep changes, weight gain, and decreased libido. However, more serious adverse events such as venous thromboembolic disease and endometrial hyperplasia or cancer are the most clinically significant. The article presents the results of a retrospective population-based study on assessing hyperplastic processes of the endometrium (HPE) in patients with breast cancer during TAM therapy, conducted in 2017, approved by the Ethics Committee of the Scientific Research of the Russian Medical Academy of Continuing Professional Education.
Aim. To identify clinical factors that may increase the risk of HPE during tamoxifen therapy in patients with a history of breast cancer living in the Moscow region.
Materials and methods. We retrospectively reviewed 230 case histories of patients with breast cancer. Of these, 120 patients who received TAM therapy had the following HPE risk factors: average age, menopausal status, body mass index, and duration of TAM therapy.
Results. It was found that patients with HPE taking TAM were older (p=0.017), more likely to be postmenopausal (p=0.035), overweight (p=0.023), and received TAM for a longer period (p=0.028) than patients without HPE.
Conclusion. The data obtained indicate the need for continuous monitoring by gynecologists of patients with breast cancer taking tamoxifen, paying particular attention to women from high-risk groups, namely older postmenopausal women with high body mass index receiving TAM for more than 1.5–2 years.
Full Text
##article.viewOnOriginalSite##About the authors
Ekaterina O. Golubenko
Russian Medical Academy of Continuous Professional Education
Author for correspondence.
Email: kate.golubenko@yandex.ru
ORCID iD: 0000-0002-6968-862X
Obstetrician-Gynecologist, Competitor of the Department of Obstetrics and Gynecology, Russian Medical Academy of Continuous Professional Education
Russian Federation, MoscowMarina I. Savelyeva
Yaroslavl State Medical University
Email: marinasavelyeva@mail.ru
ORCID iD: 0000-0002-2373-2250
SPIN-code: 2434-6458
D. Sci. (Med.), Yaroslavl State Medical University
Russian Federation, YaroslavlIrina V. Poddubnaya
Russian Medical Academy of Continuous Professional Education
Email: ivprectorat@inbox.ru
ORCID iD: 0000-0002-0995-1801
SPIN-code: 1146-9889
Acad. RAS, D. Sci. (Med.), Prof., Russian Medical Academy of Continuous Professional Education
Russian Federation, MoscowVera V. Korennaya
Russian Medical Academy of Continuous Professional Education
Email: drkorennaya@mail.ru
ORCID iD: 0000-0003-1104-4415
Cand. Sci. (Med.), Russian Medical Academy of Continuous Professional Education
Russian Federation, MoscowReferences
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-717. doi: 10.1016/S0140-6736(05)66544-0
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771-84. doi: 10.1016/S0140-6736(11)60993-8
- Massarweh S, Schiff R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res. 2007;13(7):50-4. doi: 10.1158/1078-0432.CCR-06-2540
- Burstein HJ, Griggs JJ, Prestrud AA, Temin S. American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Oncol Pract. 2010;6(5):243-6. doi: 10.1200/JOP.000082
- Schiavon G, Smith IE. Endocrine therapy for advanced/metastatic breast cancer. Hematol Oncol Clin North Am. 2013;27(4):715-36. doi: 10.1016/j.hoc.2013.05.004
- Lee M, Piao J, Jeon MJ. Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen. Yonsei Med J. 2020;61(4):317-22. doi: 10.3349/ymj.2020.61.4.317
- Condorelli R, Vaz-Luis I. Managing side effects in adjuvant endocrine therapy for breast cancer. Expert Rev Anticancer Ther. 2018;18(11):1101-12. doi: 10.1080/14737140.2018.1520096
- Yang G, Nowsheen S, Aziz K, Georgakilas AG. Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs. Pharmacol Ther. 2013;139(3):392-404. doi: 10.1016/j.pharmthera.2013.05.005
- Ganz PA. Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life. J Natl Cancer Inst Monogr. 2001;(30):130-4. doi: 10.1093/oxfordjournals.jncimonographs.a003450
- Lorizio W, Wu AH, Beattie MS, et al. Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat. 2012;132(3):1107-18. doi: 10.1007/s10549-011-1893-4
- Ивашина С.В., Бабаева Н.А. Моцкобили Т.А., и др. Атрофия или гиперплазия эндометрия? Тактика ведения пациенток на фоне антиэстрогенной терапии. Онкология. Журнал им. П.А. Герцена. 2022;11(2):13-9 [Ivashina SV, Babaeva NA, Motskobili TA, et al. Endometrial atrophy or hyperplasia? Patient management tactics against the background of antiestrogen therapy. PA Herzen Journal of Oncology. 2022;11(2):13-9 (in Russian)]. doi: 10.17116/onkolog20221102113
- Royal College of Obstetricians and Gynaecoloists. Management of endometrial hyperplasia. Green-top Guidline No. 67 RCOG/BSGE Joint Guidline. London, 2016.
- Jones ME, van Leeuwen FE, Hoogendoorn WE, et al. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: Pooled results from three countries. BCR. 2012;14(3):R91. doi: 10.1186/bcr3206
- Juneja M, Jose R, Kekre AN, et al. Tamoxifen-induced endometrial changes in postmenopausal women with breast carcinoma. Int J Gynaecol Obstet. 2002;76(3):279-84. doi: 10.1016/S0020-7292(01)00528-8
- Lachance JA, Everett EN, Greer B, et al. The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol. 2006;101(3):470-5. doi: 10.1016/j.ygyno.2005.11.009
- Серов В.Н. Климактерический период: нормальное состояние или патология. РМЖ. 2002;18:791 [Serov VN. Klimaktericheskii period: normal'noie sostoyaniie ili patologiia. RMZH. 2002;18:791 (in Russian)].
- Rastogi P. Chemoprevention in postmenopausal women. Menopause. 2008;15(Suppl. 4):810-5. doi: 10.1097/gme.0b013e318178863e
- Bergman L, Beelen MLR, Gallee MPW, et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet. 2000;356(9233):881-7.
- Wise MR, Jordan V, Lagas A, et al. Obesity and endometrial hyperplasia and cancer in premenopausal women: A systematic review. Am J Obstet Gynecol. 2016;214(6):689.e1-17. doi: 10.1016/j.ajog.2016.01.175
- Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569-78. doi: 10.1016/S0140-6736(08)60269-X
- Dignam JJ, Wieand K, Johnson KA, et al. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst. 2003;95(19):1467-76. doi: 10.1093/jnci/djg060
- Jindal A, Mohi MK, Kaur M, et al. Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy. J Midlife Health. 2015;6(2):59-65. doi: 10.4103/0976-7800.158947
- Новикова Е.Г., Никанорова Л.В. Длительный прием тамоксифена при распространенном раке молочной железы – преимущества и определенный риск. Высокие технологии в онкологии. Материалы V Всероссийского съезда онкологов (г. Казань, 4–7 октября 2000 г.). РГМУ: РНИОИ, 2000. Т. 3; с. 69-70 [Novikova YeG, Nikanorova LV. Dlitel'nyi priiem tamoksifena pri rasprostranennom rake molochnoi zhelezy – preimushchestva i opredelennyi risk. Vysokiie tekhnologii v onkologii. Materialy V Vserossiiskogo s"iezda onkologov (g. Kazan', 4–7 oktiabria 2000 g.). RGMU: RNIOI, 2000. T. 3; p. 69-70 (in Russian)].